EVEGEN’S Breakthrough Research On FHV-1 Published In Springer Nature
Jul 03,2025
We are pleased to announce that our research on Feline Herpesvirus Type 1 (FHV-1) has been published in Springer Nature-a leading global academic publisher. The success of this research is primarily attributed to the efforts of our R&D team, as well as our collaborators from Shanxi Agricultural University and Inner Mongolia Agricultural University.
Since its discovery in 1958, feline herpesvirus type 1 (FHV-1) has spread worldwide, posing a serious threat to both domestic and wild cats. As one of the most significant feline pathogens, FHV-1 continues to impact cat health globally. Currently, no universally approved vaccine provides full protection against FHV-1. As such, the development of a rapid, efficient, and highly sensitive diagnostic method is essential for preventing and managing FHV-1 infections in feline populations.
In this study, we developed an immunochromatographic lateral flow (ICLF) assay for rapid detection of FHV-1-specific antibodies. The assay was based on a 26 kDa recombinant glycoprotein B-glycoprotein D (gB-gD) fusion protein, which was successfully expressed, purified, and employed as the capture antigen.
Key Innovations & Achievements
The assay utilizes a recombinant gB-gD fusion protein as the capture antigen, offering superior reliability compared to traditional methods like ELISA or PCR.
Demonstrated exceptional performance in clinical validation:
✅ High Accuracy: 97% sensitivity and 100% specificity in clinical testing
✅ Fast & Easy: Results in 10 minutes, no specialized equipment required
✅ Long Shelf Life: Stable for 24 months at room temperature
✅ Highly Specificity: No cross-reactivity with other common feline viruses ( Feline giardia, feline leukemia virus (FeLV), Toxoplasma gondii, feline panleukopenia virus (FPV), feline immunodeficiency virus (FIV), and Feline Coronavirus (FCoV))
Access the Research：https://doi.org/10.1186/s44149-025-00170-1
联系我们